The Latest Breaking News from Moderna

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

Moderna has partnered with another drug company to produce a personalised vaccine against melanoma for people at risk of dying.

Thank you, science.

The stock market's reaction to the inflation data was swift and decisive.

Shares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring.

The decision aims to better protect the littlest kids amid an uptick in COVID-19 cases around the country. The Centers for Disease Control and Prevention is expected to sign off soon.

Biotech giant Moderna's first mRNA vaccine facility in Australia is due to open in 2024, and will produce 100 million vaccine doses per year.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.